2025 American BP guidelines
The U.S. hypertension guideline updates screening, treatment thresholds, and condition-specific management.1 Screening for primary aldosteronism is now recommended for all cases of resistant hypertension, and most antihypertensives (except MRAs) should be continued during testing.
Potassium-based salt substitutes may help lower BP except in CKD or impaired potassium excretion. Medication with treatment recommended at ≥130/80 mm Hg for higher-risk groups and after lifestyle trials for lower-risk groups. ACEi/ARB use is strengthened for diabetes and CKD with albuminuria (Candesartan is recommended in NZ).
Pregnancy recommendations emphasise rapid treatment of severe hypertension, treating chronic hypertension to <140/90, giving low-dose aspirin, and avoiding ACEi/ARB, atenolol, MRAs, and renin inhibitors.
Resistant hypertension management includes multidisciplinary evaluation and careful medication review.
Check for secondary causes in under-40-year-olds' renal artery stenosis, pheochromocytoma, primary aldosteronism and Cushing's pheochromocytoma or paraganglioma, drugs, e.g. methamphetamine and alcohol.
Click here to view more Gems |
Goodfellow Gems are chosen by Goodfellow Director, Prof Bruce Arroll to be either practice changing or thought provoking. If this email was forwarded to you and you would like to automatically receive Goodfellow Gems Click here.